Europe's regulator attacked for "secrecy" over drug data
This article was originally published in Scrip
Executive Summary
There are new calls for the European Medicines Agency (EMA) to provide greater transparency about the evidence it uses to make decisions about drug approvals. The EMA has strongly defended itself in response, saying its hands are tied by legislation regarding commercially confidential clinical trial data.